Literature DB >> 32668444

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Nina Le Bert1, Anthony T Tan1, Kamini Kunasegaran1, Christine Y L Tham1, Morteza Hafezi1, Adeline Chia1, Melissa Hui Yen Chng1, Meiyin Lin1,2, Nicole Tan1, Martin Linster1, Wan Ni Chia1, Mark I-Cheng Chen3, Lin-Fa Wang1, Eng Eong Ooi1, Shirin Kalimuddin4, Paul Anantharajah Tambyah5,6, Jenny Guek-Hong Low1,4, Yee-Joo Tan2,7, Antonio Bertoletti8,9.   

Abstract

Memory T cells induced by previous pathogens can shape susceptibility to, and the clinical severity of, subsequent infections1. Little is known about the presence in humans of pre-existing memory T cells that have the potential to recognize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we studied T cell responses against the structural (nucleocapsid (N) protein) and non-structural (NSP7 and NSP13 of ORF1) regions of SARS-CoV-2 in individuals convalescing from coronavirus disease 2019 (COVID-19) (n = 36). In all of these individuals, we found CD4 and CD8 T cells that recognized multiple regions of the N protein. Next, we showed that patients (n = 23) who recovered from SARS (the disease associated with SARS-CoV infection) possess long-lasting memory T cells that are reactive to the N protein of SARS-CoV 17 years after the outbreak of SARS in 2003; these T cells displayed robust cross-reactivity to the N protein of SARS-CoV-2. We also detected SARS-CoV-2-specific T cells in individuals with no history of SARS, COVID-19 or contact with individuals who had SARS and/or COVID-19 (n = 37). SARS-CoV-2-specific T cells in uninfected donors exhibited a different pattern of immunodominance, and frequently targeted NSP7 and NSP13 as well as the N protein. Epitope characterization of NSP7-specific T cells showed the recognition of protein fragments that are conserved among animal betacoronaviruses but have low homology to 'common cold' human-associated coronaviruses. Thus, infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein. Understanding how pre-existing N- and ORF1-specific T cells that are present in the general population affect the susceptibility to and pathogenesis of SARS-CoV-2 infection is important for the management of the current COVID-19 pandemic.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32668444     DOI: 10.1038/s41586-020-2550-z

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  675 in total

1.  SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.

Authors:  Bezawit A Woldemeskel; Caroline C Garliss; Joel N Blankson
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

2.  RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells.

Authors:  Taisho Yamada; Seiichi Sato; Yuki Sotoyama; Yasuko Orba; Hirofumi Sawa; Hajime Yamauchi; Michihito Sasaki; Akinori Takaoka
Journal:  Nat Immunol       Date:  2021-05-11       Impact factor: 25.606

3.  BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of health care workers.

Authors:  Magali Noval Rivas; Joseph E Ebinger; Min Wu; Nancy Sun; Jonathan Braun; Kimia Sobhani; Jennifer E Van Eyk; Susan Cheng; Moshe Arditi
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 4.  Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity.

Authors:  Rudragouda Channappanavar; Stanley Perlman
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

5.  Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2.

Authors:  Bezawit A Woldemeskel; Abena K Kwaa; Caroline C Garliss; Oliver Laeyendecker; Stuart C Ray; Joel N Blankson
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

6.  Recent endemic coronavirus infection is associated with less-severe COVID-19.

Authors:  Manish Sagar; Katherine Reifler; Michael Rossi; Nancy S Miller; Pranay Sinha; Laura F White; Joseph P Mizgerd
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 7.  The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2.

Authors:  Jack A Collora; Runxia Liu; Kristen Albrecht; Ya-Chi Ho
Journal:  Curr Opin HIV AIDS       Date:  2021-01       Impact factor: 4.283

8.  Protracted yet Coordinated Differentiation of Long-Lived SARS-CoV-2-Specific CD8+ T Cells during Convalescence.

Authors:  Tongcui Ma; Heeju Ryu; Matthew McGregor; Benjamin Babcock; Jason Neidleman; Guorui Xie; Ashley F George; Julie Frouard; Victoria Murray; Gurjot Gill; Eliver Ghosn; Evan W Newell; Sulggi A Lee; Nadia R Roan
Journal:  J Immunol       Date:  2021-08-13       Impact factor: 5.422

9.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.

Authors:  Annika Nelde; Tatjana Bilich; Jonas S Heitmann; Yacine Maringer; Helmut R Salih; Malte Roerden; Maren Lübke; Jens Bauer; Jonas Rieth; Marcel Wacker; Andreas Peter; Sebastian Hörber; Bjoern Traenkle; Philipp D Kaiser; Ulrich Rothbauer; Matthias Becker; Daniel Junker; Gérard Krause; Monika Strengert; Nicole Schneiderhan-Marra; Markus F Templin; Thomas O Joos; Daniel J Kowalewski; Vlatka Stos-Zweifel; Michael Fehr; Armin Rabsteyn; Valbona Mirakaj; Julia Karbach; Elke Jäger; Michael Graf; Lena-Christin Gruber; David Rachfalski; Beate Preuß; Ilona Hagelstein; Melanie Märklin; Tamam Bakchoul; Cécile Gouttefangeas; Oliver Kohlbacher; Reinhild Klein; Stefan Stevanović; Hans-Georg Rammensee; Juliane S Walz
Journal:  Nat Immunol       Date:  2020-09-30       Impact factor: 25.606

10.  The coSIR model predicts effective strategies to limit the spread of SARS-CoV-2 variants with low severity and high transmissibility.

Authors:  Longchen Xu; Haohang Zhang; Hengyi Xu; Han Yang; Lei Zhang; Wei Zhang; Fei Gu; Xun Lan
Journal:  Nonlinear Dyn       Date:  2021-07-23       Impact factor: 5.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.